老年乳腺癌生存者癌症相关认知结局:Thinking and Living With Cancer 研究
该研究纳入新诊断非转移性乳腺癌生存者344例与匹配无癌对照347例(均≥60岁、无痴呆或神经系统疾病),于系统治疗前/入组时及12、24个月评估认知。结果显示化疗与APE评分进行性变差相关(P=.05),启动内分泌治疗者12个月LM评分较低(P=.03);ApoE基因型影响组间差异。
要点
- 老年乳腺癌生存者化疗与APE评分进行性下降相关(P=.05)
- 启动内分泌治疗者12个月LM评分低于其他组(P=.03)
- 仅ε4+接受内分泌治疗者出现短期调整LM评分下降(三项交互P=.03)
核心结论
- 乳腺癌系统治疗与衰老相关表型和基因型与老年生存者认知功能评分的纵向下降相关。
- 这些数据可用于治疗决策和生存期照护规划。
研究设计与样本
- 前瞻性队列研究,2010年8月至2015年12月招募新诊断非转移性乳腺癌生存者344例与匹配无癌对照347例,均≥60岁且无痴呆或神经系统疾病。
- 于系统治疗前/对照入组时及12、24个月收集生物标本、问卷、自报FACT-Cognitive Function及神经心理测试(APE与LM)。
- 采用线性混合效应模型检验治疗组与时间的两项交互,并探索ApoE(ε4+ vs 非ε4+)×组×时间三项交互;协变量包括基线年龄、衰弱、种族和认知储备。
主要发现
- 生存者与对照年龄60至98岁、教育程度良好、基线认知评分相似。
- 接受化疗的生存者APE评分进行性变差(P=.05),启动内分泌治疗者12个月LM评分低于其他组(P=.03)。
- 仅接受内分泌治疗的ε4+生存者出现短期调整LM评分下降(三项交互P=.03)。
- APE三项交互不显著(P=.14),但24个月时暴露于化疗的ε4+生存者评分显著低于ε4+对照(-0.40;95%CI,-0.79至-0.01 vs 0.01;95%CI,0.16至0.18;P<.05)。
- 年龄增加与所有认知指标基线评分较低相关(P<.001);衰弱与基线APE及自报认知下降相关(P<.001)。
临床怎么用
- 对老年乳腺癌患者制定系统治疗决策时,应纳入认知功能下降风险的考量。
- 对接受化疗或内分泌治疗的老年生存者,尤其ApoE ε4+者,可考虑认知功能监测与生存期照护规划。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To determine treatment and aging-related effects on longitudinal cognitive function in older breast cancer survivors. METHODS: Newly diagnosed nonmetastatic breast cancer survivors (n = 344) and matched controls without cancer (n = 347) 60 years of age and older without dementia or neurologic disease were recruited between August 2010 and December 2015. Data collection occurred during presystemic treatment/control enrollment and at 12 and 24 months through biospecimens; surveys; self-reported Functional Assessment of Cancer Therapy-Cognitive Function; and neuropsychological tests that measured attention, processing speed, and executive function (APE) and learning and memory (LM). Linear mixed-effects models tested two-way interactions of treatment group (control, chemotherapy with or without hormonal therapy, and hormonal therapy) and time and explored three-way interactions of ApoE (ε4+ v not) by group by time; covariates included baseline age, frailty, race, and cognitive reserve. RESULTS: Survivors and controls were 60 to 98 years of age, were well educated, and had similar baseline cognitive scores. Treatment was related to longitudinal cognition scores, with survivors who received chemotherapy having increasingly worse APE scores ( P = .05) and those initiating hormonal therapy having lower LM scores at 12 months ( P = .03) than other groups. These group-by-time differences varied by ApoE genotype, where only ε4+ survivors receiving hormone therapy had short-term decreases in adjusted LM scores (three-way interaction P = .03). For APE, the three-way interaction was not significant ( P = .14), but scores were significantly lower for ε4+ survivors exposed to chemotherapy (-0.40; 95% CI, -0.79 to -0.01) at 24 months than ε4+ controls (0.01; 95% CI, 0.16 to 0.18; P < .05). Increasing age was associated with lower baseline scores on all cognitive measures ( P < .001); frailty was associated with baseline APE and self-reported decline ( P < .001). CONCLUSION: Breast cancer systemic treatment and aging-related phenotypes and genotypes are associated with longitudinal decreases in cognitive function scores in older survivors. These data could inform treatment decision making and survivorship care planning.
引用
- Mandelblatt JS, Small BJ, Luta G, et al. Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. J Clin Oncol. 2018. PMID: 30281396. doi:10.1200/JCO.18.00140
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。